124 related articles for article (PubMed ID: 20687215)
1. Loss of the matriptase inhibitor HAI-2 during prostate cancer progression.
Bergum C; List K
Prostate; 2010 Sep; 70(13):1422-8. PubMed ID: 20687215
[TBL] [Abstract][Full Text] [Related]
2. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
[TBL] [Abstract][Full Text] [Related]
3. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
Oberst MD; Johnson MD; Dickson RB; Lin CY; Singh B; Stewart M; Williams A; al-Nafussi A; Smyth JF; Gabra H; Sellar GC
Clin Cancer Res; 2002 Apr; 8(4):1101-7. PubMed ID: 11948120
[TBL] [Abstract][Full Text] [Related]
4. Strong expression association between matriptase and its substrate prostasin in breast cancer.
Bergum C; Zoratti G; Boerner J; List K
J Cell Physiol; 2012 Apr; 227(4):1604-9. PubMed ID: 21678412
[TBL] [Abstract][Full Text] [Related]
5. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer.
Nagakawa O; Yamagishi T; Akashi T; Nagaike K; Fuse H
Prostate; 2006 Apr; 66(5):447-52. PubMed ID: 16353247
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
[TBL] [Abstract][Full Text] [Related]
7. Expression of Hepatocyte growth factor activator inhibitor type-1 (HAI-1) in prostate cancer.
Yasuda K; Komiya A; Watanabe A; Morii A; Oya T; Nagakawa O; Fujiuchi Y; Fuse H
Anticancer Res; 2013 Feb; 33(2):575-81. PubMed ID: 23393351
[TBL] [Abstract][Full Text] [Related]
8. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
9. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
10. Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis.
Warren M; Twohig M; Pier T; Eickhoff J; Lin CY; Jarrard D; Huang W
Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):23-30. PubMed ID: 18813126
[TBL] [Abstract][Full Text] [Related]
11. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
[TBL] [Abstract][Full Text] [Related]
12. Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer.
Merseburger AS; Kramer MW; Hennenlotter J; Simon P; Knapp J; Hartmann JT; Stenzl A; Serth J; Kuczyk MA
Prostate; 2008 Jan; 68(1):72-7. PubMed ID: 18008332
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia.
Jackson MW; Bentel JM; Tilley WD
J Urol; 1997 Jun; 157(6):2323-8. PubMed ID: 9146664
[TBL] [Abstract][Full Text] [Related]
14. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate.
Ravindranath N; Wion D; Brachet P; Djakiew D
J Androl; 2001; 22(3):432-43. PubMed ID: 11330643
[TBL] [Abstract][Full Text] [Related]
16. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer.
Alberti I; Barboro P; Barbesino M; Sanna P; Pisciotta L; Parodi S; Nicolò G; Boccardo F; Galli S; Patrone E; Balbi C
J Cell Biochem; 2000 Sep; 79(3):471-85. PubMed ID: 10972984
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of the leptin and leptin receptor expressions in prostate tissues.
Hoon Kim J; Lee SY; Myung SC; Kim YS; Kim TH; Kim MK
Asian J Androl; 2008 Nov; 10(6):923-8. PubMed ID: 18958356
[TBL] [Abstract][Full Text] [Related]
18. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.
Guo Y; Sklar GN; Borkowski A; Kyprianou N
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2269-74. PubMed ID: 9815624
[TBL] [Abstract][Full Text] [Related]
19. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
Soulitzis N; Karyotis I; Delakas D; Spandidos DA
Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
[TBL] [Abstract][Full Text] [Related]
20. The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.
Wu SR; Teng CH; Tu YT; Ko CJ; Cheng TS; Lan SW; Lin HY; Lin HH; Tu HF; Hsiao PW; Huang HP; Chen CH; Lee MS
Sci Rep; 2017 Nov; 7(1):15101. PubMed ID: 29118397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
